Chromosomal imbalance in the progression of high-risk non-muscle invasive bladder cancer

被引:11
|
作者
Zieger, Karsten [1 ,2 ]
Wiuf, Carsten [3 ]
Jensen, Klaus Moller-Ernst [2 ]
Orntoft, Torben Falck [1 ]
Dyrskjot, Lars [1 ]
机构
[1] Aarhus Univ Hosp Skejby, Dept Mol Med, Aarhus N, Denmark
[2] Aarhus Univ Hosp Skejby, Dept Urol, Aarhus N, Denmark
[3] Aarhus Univ, Bioinformat Res Ctr, Aarhus, Denmark
来源
BMC CANCER | 2009年 / 9卷
关键词
COMPARATIVE GENOMIC HYBRIDIZATION; NUCLEOTIDE POLYMORPHISM ARRAYS; TRANSITIONAL-CELL CARCINOMA; DNA COPY NUMBER; UROTHELIAL CARCINOMAS; URINARY-BLADDER; FOLLOW-UP; TUMORS; STAGE; RECURRENCE;
D O I
10.1186/1471-2407-9-149
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Non-muscle invasive bladder neoplasms with invasion of the lamina propria (stage T1) or high grade of dysplasia are at "high risk" of progression to life-threatening cancer. However, the individual course is difficult to predict. Chromosomal instability (CI) is associated with high tumor stage and grade, and possibly with the risk of progression. Methods: To investigate the relationship between CI and subsequent disease progression, we performed a case-control-study of 125 patients with "high-risk" non-muscle invasive bladder neoplasms, 67 with later disease progression, and 58 with no progression. Selection criteria were conservative (non-radical) resections and full prospective clinical follow-up (> 5 years). We investigated primary lesions in 59, and recurrent lesions in 66 cases. We used Affymetrix GeneChip (R) Mapping 10 K and 50 K SNP microarrays to evaluate genome wide chromosomal imbalance (loss-of-heterozygosity and DNA copy number changes) in 48 representative tumors. DNA copy number changes of 15 key instability regions were further investigated using QPCR in 101 tumors (including 25 tumors also analysed on 50 K SNP microarrays). Results: Chromosomal instability did not predict any higher risk of subsequent progression. Stage T1 and high-grade tumors had generally more unstable genomes than tumors of lower stage and grade (mostly non-primary tumors following a "high-risk" tumor). However, about 25% of the "high-risk" tumors had very few alterations. This was independent of subsequent progression. Recurrent lesions represent underlying field disease. A separate analysis of these lesions did neither reflect any difference in the risk of progression. Of specific chromosomal alterations, a possible association between loss of chromosome 8p11 and the risk of progression was found. However, the predictive value was limited by the heterogeneity of the changes. Conclusion: Chromosomal instability (CI) was associated with "high risk" tumors (stage T1 or high-grade), but did not predict subsequent progression. Recurrences after "high-risk" tumors had fewer chromosomal alterations, but there was no association with the risk of progression in this group either. Thus, the prediction of progression of "high risk" non-muscle invasive bladder tumors using chromosomal changes is difficult. Loss of chromosome 8p11 may play a role in the progression process. About 25% of the " high risk" tumors were chromosomal stable.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Chromosomal imbalance in the progression of high-risk non-muscle invasive bladder cancer
    Karsten Zieger
    Carsten Wiuf
    Klaus Møller-Ernst Jensen
    Torben Falck Ørntoft
    Lars Dyrskjøt
    [J]. BMC Cancer, 9 (1)
  • [2] Chromosomal Imbalance in the Progression of High-Risk Non-Muscle Invasive Bladder Cancer Editorial Comment
    Montie, James E.
    [J]. JOURNAL OF UROLOGY, 2010, 183 (03): : 938 - 939
  • [3] Management of high-risk non-muscle invasive bladder cancer
    Brausi, M.
    Olaru, V.
    [J]. MINERVA UROLOGICA E NEFROLOGICA, 2012, 64 (04) : 255 - 260
  • [4] Pembrolizumab monotherapy for high-risk, non-muscle invasive bladder cancer
    Balar, Arjun, V
    Kamat, Ashish M.
    de Wit, Ronald
    [J]. LANCET ONCOLOGY, 2021, 22 (09): : E380 - E380
  • [5] Novel Therapies for High-Risk Non-Muscle Invasive Bladder Cancer
    Bashir Al Hussein Al Awamlh
    Sam S. Chang
    [J]. Current Oncology Reports, 2023, 25 : 83 - 91
  • [6] Genomic characterization of high-risk non-muscle invasive bladder cancer
    Meeks, Joshua J.
    Carneiro, Benedito A.
    Pai, Sachin G.
    Oberlin, Daniel T.
    Rademaker, Alfred
    Fedorchak, Kyle
    Balasubramanian, Sohail
    Elvin, Julia
    Beaubier, Nike
    Giles, Francis J.
    [J]. ONCOTARGET, 2016, 7 (46) : 75176 - 75184
  • [7] Novel Therapies for High-Risk Non-Muscle Invasive Bladder Cancer
    Al Awamlh, Bashir Al Hussein
    Chang, Sam S.
    [J]. CURRENT ONCOLOGY REPORTS, 2023, 25 (02) : 83 - 91
  • [8] Tumor mutation burden to predict progression in high-risk non-muscle invasive bladder cancer.
    Meeks, Joshua
    Carneiro, Benedito A.
    Pai, Sachin Gopalkrishn
    Oberlin, Daniel
    Rademaker, Alfred
    Fedorchak, Kyle
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [9] THE OUTCOME OF PATIENTS WITH HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER IN SWEDEN
    Wang, Eugen
    Larsson, Ulf
    Gardmark, Truls
    Malmstrom, Per-Uno
    [J]. JOURNAL OF UROLOGY, 2020, 203 : E1077 - E1077
  • [10] Current approaches for identifying high-risk non-muscle invasive bladder cancer
    Sanli, Oner
    Lotan, Yair
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (03) : 223 - 235